Privia Health Reports Strong Q4 2025 Earnings and Growth Outlook
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 26 2026
0mins
Should l Buy PRVA?
Source: seekingalpha
- Significant Performance Growth: Privia Health's practice collections increased by 16.9% to $3.47 billion in 2025, while adjusted EBITDA grew by 38.8% to $125.5 million, demonstrating the company's strong execution and growth potential in the market.
- Provider Expansion: The addition of 591 new providers resulted in a year-over-year growth rate of 12.3%, bringing the total implemented providers to 5,380, with expectations to reach 5,950 by the end of 2026, further solidifying market position.
- Successful Acquisition Integration: The completion of the Evolent Health ACO business acquisition added over 120,000 value-based attributed lives, marking the company's expansion into Arizona and strengthening the foundation for future growth.
- Optimistic Cash Flow Outlook: The company projects approximately 20% growth in adjusted EBITDA for 2026, with an 80% conversion rate to free cash flow, maintaining around $600 million in cash reserves to support future business development.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PRVA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PRVA
Wall Street analysts forecast PRVA stock price to rise
12 Analyst Rating
11 Buy
1 Hold
0 Sell
Strong Buy
Current: 21.030
Low
23.00
Averages
30.40
High
34.00
Current: 21.030
Low
23.00
Averages
30.40
High
34.00
About PRVA
Privia Health Group, Inc. is a technology-driven, national physician-enablement company. The Company collaborates with medical groups, health plans and health systems. It enhances physician practices, improves patient experiences and doctors for delivering care in both in-person and virtual care settings. Its Privia Platform is powered by the Privia Technology Solution, an end-to-end, cloud-based technology solution that integrates both Privia-developed and third-party applications into an interface and workflow that manages all aspects of its Privia Providers provision of healthcare services. Privia Platform optimizes provider workflow across the full continuum of reimbursement arrangements. The Company provides management services to each Medical Group though a local management services organization, which provides Medical Groups with access to value-based care (VBC) opportunities either directly or through Privia-owned accountable care organizations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Privia Health CFO Sells Shares for Tax Obligations
- Executive Stock Sale: David Mountcastle, CFO of Privia Health, sold 13,018 shares between March 12 and 13, 2026, for approximately $283,000 at an average price of $21.71 per share, representing 5.24% of his total direct holdings.
- Tax Obligation Reason: The sale was strictly for tax withholding obligations related to the vesting of performance stock units, indicating that investors should not interpret this transaction as a negative signal for PRVA stock, but rather focus on the company's fundamentals.
- Strong Financial Performance: Despite a 10% decline in PRVA's stock price in 2026, the company exceeded earnings expectations in its Q4 FY 2025 report, posting 7 cents per share, surpassing the 4-cent estimate and marking the highest year-over-year growth since Q3 2023.
- Market Expansion Potential: Privia's acquisition of an Accountable Care Organization in late September 2025 added approximately 1.5 million customers, showcasing the company's growth potential in value-based operations, although analysts remain cautious about its future performance.
See More
Privia Health CFO Sells Shares for Tax Obligations
- Transaction Overview: Privia Health CFO David Mountcastle sold 13,018 shares on March 12 and 13, 2026, for approximately $283,000, indicating a necessary action for tax obligations related to stock vesting.
- Ownership Percentage Change: This transaction reduced Mountcastle's direct holdings by 5.24%, leaving him with 226,804 shares directly held, which represents a 0.18% stake in the company's outstanding shares, reflecting changes in ownership structure.
- Stable Financial Performance: Despite a 10.15% decline in PRVA stock in 2026, the company exceeded earnings expectations in its Q4 FY 2025 report, posting earnings of $0.07 per share, significantly above the $0.04 estimate, demonstrating resilience in its fundamentals.
- Customer Base Expansion: By acquiring an Accountable Care Organization (ACO), Privia gained approximately 1.5 million customers with medical plans such as Medicare, Medicare Advantage, and Medicaid, indicating growth potential in its value-based operations.
See More
Privia Health CFO Sells $283,000 Worth of Shares to Cover Taxes
- Transaction Overview: David Mountcastle, CFO of Privia Health Group, sold 13,018 shares between March 12 and 13, 2026, for approximately $283,000, indicating a liquidity move to cover tax obligations.
- Ownership Impact: This sale reduced Mountcastle's direct holdings by 5.24%, leaving him with 226,804 shares and a mere 0.18% stake in the company, which may raise concerns about management stability among investors.
- Financial Context: Despite a 10.15% decline in PRVA's stock price in 2026, the company reported strong Q4 FY 2025 earnings, posting 7 cents per share, exceeding the 4-cent estimate, showcasing financial resilience.
- Market Reaction Advice: As the share sale was strictly for tax withholding related to the vesting of performance stock units, investors should not interpret this transaction negatively, especially given the company's acquisition of 1.5 million customers through an Accountable Care Organization, indicating potential for future growth.
See More
BlackBarn Capital Increases Warby Parker Stake by 2 Million Shares
- Stake Increase: BlackBarn Capital increased its stake in Warby Parker by 2 million shares during Q4 2025, with an estimated transaction value of $43.52 million, indicating confidence in the company despite a 15% decline in its stock price over the past year.
- Value Appreciation: The value of Warby Parker's position rose by $37.79 million at quarter-end, reflecting the impact of trading activity and stock price fluctuations, suggesting that BlackBarn Capital's investment strategy is proving effective.
- Asset Allocation Shift: Following the increase, Warby Parker now accounts for 4.3% of BlackBarn Capital's 13F reportable assets, indicating its significance in the investment portfolio, even though it does not rank among the top five holdings.
- Market Performance Insight: As of February 13, 2026, Warby Parker shares were priced at $22.46, underperforming the S&P 500 by 26.8 percentage points, prompting investors to monitor the company's ability to achieve sustainable growth in the optical retail market.
See More
BlackBarn Capital Increases Warby Parker Stake to 3 Million Shares
- Share Increase: According to a recent SEC filing dated February 17, 2026, BlackBarn Capital Partners LP acquired an additional 2 million shares of Warby Parker, raising its total stake to 3 million shares, with an estimated transaction value of $43.52 million, reflecting confidence in the company's growth potential.
- Asset Management Proportion: Warby Parker now accounts for 4.3% of BlackBarn Capital's reportable assets under management, indicating its significance in the firm's 13F report and investor recognition of its potential value.
- Market Performance: As of February 13, 2026, Warby Parker shares were priced at $22.46, down 15% over the past year and underperforming the S&P 500 by 26.8 percentage points, highlighting market concerns regarding its future growth.
- Business Model Analysis: Warby Parker challenges traditional eyewear retail economics through a direct-to-consumer model, and while facing high costs and competitive pressures, its expanding exam capacity may ultimately be key to its future profitability.
See More
EHR-Enabled Colorectal Cancer Screening Achieves Significant Impact
- Screening Rate Increase: The colorectal cancer screening program led by Privia Health achieved an 84% screening rate in 2024, surpassing national benchmarks and the National Colorectal Cancer Roundtable's 80% goal, demonstrating the effectiveness of data-driven patient engagement models.
- Patient Engagement Scale: The program successfully engaged over 42,000 patients through automated outreach, with plans to expand nationally to over 100,000 patients, significantly enhancing the reach and efficiency of screenings.
- Diagnostic Follow-Up Rate: Within a 48-hour window, approximately 23,000 screening orders were processed, yielding a 10% positivity rate that identified over 550 patients requiring further diagnostic follow-up, indicating the program's potential in early cancer detection.
- Support for Value-Based Care: The initiative not only improved screening outcomes but also strengthened patient identification and documentation quality, supporting electronic clinical quality measure (eCQM) reporting and positioning health systems to meet future digital quality measurement requirements.
See More
Privia Health CFO Sells Shares for Tax Obligations
- Executive Stock Sale: David Mountcastle, CFO of Privia Health, sold 13,018 shares between March 12 and 13, 2026, for approximately $283,000 at an average price of $21.71 per share, representing 5.24% of his total direct holdings.
- Tax Obligation Reason: The sale was strictly for tax withholding obligations related to the vesting of performance stock units, indicating that investors should not interpret this transaction as a negative signal for PRVA stock, but rather focus on the company's fundamentals.
- Strong Financial Performance: Despite a 10% decline in PRVA's stock price in 2026, the company exceeded earnings expectations in its Q4 FY 2025 report, posting 7 cents per share, surpassing the 4-cent estimate and marking the highest year-over-year growth since Q3 2023.
- Market Expansion Potential: Privia's acquisition of an Accountable Care Organization in late September 2025 added approximately 1.5 million customers, showcasing the company's growth potential in value-based operations, although analysts remain cautious about its future performance.
See More
Privia Health CFO Sells Shares for Tax Obligations
- Transaction Overview: Privia Health CFO David Mountcastle sold 13,018 shares on March 12 and 13, 2026, for approximately $283,000, indicating a necessary action for tax obligations related to stock vesting.
- Ownership Percentage Change: This transaction reduced Mountcastle's direct holdings by 5.24%, leaving him with 226,804 shares directly held, which represents a 0.18% stake in the company's outstanding shares, reflecting changes in ownership structure.
- Stable Financial Performance: Despite a 10.15% decline in PRVA stock in 2026, the company exceeded earnings expectations in its Q4 FY 2025 report, posting earnings of $0.07 per share, significantly above the $0.04 estimate, demonstrating resilience in its fundamentals.
- Customer Base Expansion: By acquiring an Accountable Care Organization (ACO), Privia gained approximately 1.5 million customers with medical plans such as Medicare, Medicare Advantage, and Medicaid, indicating growth potential in its value-based operations.
See More
Privia Health CFO Sells $283,000 Worth of Shares to Cover Taxes
- Transaction Overview: David Mountcastle, CFO of Privia Health Group, sold 13,018 shares between March 12 and 13, 2026, for approximately $283,000, indicating a liquidity move to cover tax obligations.
- Ownership Impact: This sale reduced Mountcastle's direct holdings by 5.24%, leaving him with 226,804 shares and a mere 0.18% stake in the company, which may raise concerns about management stability among investors.
- Financial Context: Despite a 10.15% decline in PRVA's stock price in 2026, the company reported strong Q4 FY 2025 earnings, posting 7 cents per share, exceeding the 4-cent estimate, showcasing financial resilience.
- Market Reaction Advice: As the share sale was strictly for tax withholding related to the vesting of performance stock units, investors should not interpret this transaction negatively, especially given the company's acquisition of 1.5 million customers through an Accountable Care Organization, indicating potential for future growth.
See More
BlackBarn Capital Increases Warby Parker Stake by 2 Million Shares
- Stake Increase: BlackBarn Capital increased its stake in Warby Parker by 2 million shares during Q4 2025, with an estimated transaction value of $43.52 million, indicating confidence in the company despite a 15% decline in its stock price over the past year.
- Value Appreciation: The value of Warby Parker's position rose by $37.79 million at quarter-end, reflecting the impact of trading activity and stock price fluctuations, suggesting that BlackBarn Capital's investment strategy is proving effective.
- Asset Allocation Shift: Following the increase, Warby Parker now accounts for 4.3% of BlackBarn Capital's 13F reportable assets, indicating its significance in the investment portfolio, even though it does not rank among the top five holdings.
- Market Performance Insight: As of February 13, 2026, Warby Parker shares were priced at $22.46, underperforming the S&P 500 by 26.8 percentage points, prompting investors to monitor the company's ability to achieve sustainable growth in the optical retail market.
See More
BlackBarn Capital Increases Warby Parker Stake to 3 Million Shares
- Share Increase: According to a recent SEC filing dated February 17, 2026, BlackBarn Capital Partners LP acquired an additional 2 million shares of Warby Parker, raising its total stake to 3 million shares, with an estimated transaction value of $43.52 million, reflecting confidence in the company's growth potential.
- Asset Management Proportion: Warby Parker now accounts for 4.3% of BlackBarn Capital's reportable assets under management, indicating its significance in the firm's 13F report and investor recognition of its potential value.
- Market Performance: As of February 13, 2026, Warby Parker shares were priced at $22.46, down 15% over the past year and underperforming the S&P 500 by 26.8 percentage points, highlighting market concerns regarding its future growth.
- Business Model Analysis: Warby Parker challenges traditional eyewear retail economics through a direct-to-consumer model, and while facing high costs and competitive pressures, its expanding exam capacity may ultimately be key to its future profitability.
See More
EHR-Enabled Colorectal Cancer Screening Achieves Significant Impact
- Screening Rate Increase: The colorectal cancer screening program led by Privia Health achieved an 84% screening rate in 2024, surpassing national benchmarks and the National Colorectal Cancer Roundtable's 80% goal, demonstrating the effectiveness of data-driven patient engagement models.
- Patient Engagement Scale: The program successfully engaged over 42,000 patients through automated outreach, with plans to expand nationally to over 100,000 patients, significantly enhancing the reach and efficiency of screenings.
- Diagnostic Follow-Up Rate: Within a 48-hour window, approximately 23,000 screening orders were processed, yielding a 10% positivity rate that identified over 550 patients requiring further diagnostic follow-up, indicating the program's potential in early cancer detection.
- Support for Value-Based Care: The initiative not only improved screening outcomes but also strengthened patient identification and documentation quality, supporting electronic clinical quality measure (eCQM) reporting and positioning health systems to meet future digital quality measurement requirements.
See More
